Coronado Biosciences Signs Research Collaboration And License Agreement With Freie Universitat Berlin For Secretory Products Of Trichuris Suis

BURLINGTON, Mass., Feb. 22, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today the signing of a sponsored research agreement and a joint ownership and exclusive license agreement with Freie Universität Berlin for the identification and evaluation of secretory proteins from Trichuris suis. The evaluation will be done in various pre-clinical in vitro and animal models which will further describe the mechanism of action for TSO ( Trichuris suis ova or CNDO-201) and potentially lead to newly identified immune regulatory pharmaceutical agents.

The research will be conducted by Dr. Susanne Hartmann, Professor and Head of the Institute of Immunology / Infection Immunology, Department of Veterinary Medicine, Freie Universität Berlin. Dr. Hartmann is a world-leading expert in immunology and parasitology, having led her laboratory toward novel findings on nematode-host interactions and worked extensively on Trichuris suis among other helminths.

"Coronado is very excited to be working with Dr. Hartmann on this important research collaboration," said Dr. Karin Hehenberger, Executive Vice President & Chief Medical Officer of Coronado. "Working with one of the leaders in the field will help us to further understand the mechanism of action of TSO, our lead product in phase 2 development, and may also result in the identification of novel targets and immune modulatory agents as potential therapeutic candidates for the treatment of autoimmune disease."

"Coronado Biosciences is the ideal partner to work with on this exciting project, based on experience and knowledge of using TSO as a therapeutic agent," stated Dr. Hartmann. "Our laboratory has spent the past few years focusing on the area of autoimmunity and novel ideas around nematode-host interactions, and is eager to embark on this challenging, and potentially rewarding, scientific venture."

If you liked this article you might like

Warren Buffett Pick CBI Tumbles On Rating Downgrade

Rackspace Bounces, Making Dan Loeb $34 Million In The Process

5 Biotech Stocks to Trade for Breakouts

5 Stocks Ready to Break Out

5 Stocks Under $10 Set to Soar